{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-020805","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2026-05-12T20:04:46+00:00","discovered_at":"2026-05-12T20:06:00.295312+00:00","generated_at":"2026-05-12T21:37:05.750209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuwellis Q1 net sales $2.4M (+26% YoY); gross margin 70.1%; net loss $4.3M","bullets":["Net sales $2.4M, up 26% from $1.9M YoY; gross margin 70.1% (improved 14% YoY).","Net loss $4.3M; operating expenses $6.0M (up from $4.1M) due to sales headcount.","Cash $2.2M, no debt as of March 31, 2026.","Acquired Rendiatech (kidney-function monitoring); appointed Carisa Schultz as CFO.","Appointed Martin J. Emerson and David A. McDonald to Board; new patents and TX territory."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-020805","json":"https://secwatch.observer/filing/0001140361-26-020805.json","markdown":"https://secwatch.observer/filing/0001140361-26-020805.md","text":"https://secwatch.observer/filing/0001140361-26-020805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036126020805/0001140361-26-020805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036126020805/ef20073181_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:37:05.750209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66385e26ff4616890035a6be61f8601445a78174","claim":"Nuwellis, Inc. reported the first quarter ended March 31, 2026 results: revenue $2.4 million, net income approximately $4.3 million.","evidence_excerpt":"for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights: • Net sales were $2.4 million, a 26% increase compared to the prior-year period • Gross margin improved to 70.1%, reflecting improved pricing, product mix, and the transition to contract manufacturing •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036126020805/0001140361-26-020805-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$2.4 million"},{"label":"Net income","value":"approximately $4.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}